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Abstract
This paper presents a summary of the Evidence Review Group (ERG) report into denosumab for 
the prevention of osteoporotic fractures in postmenopausal women.
Denosumab has been shown in a large randomised trial to reduce the frequency of osteoporotic 
fractures, when given subcutaneously at 6-monthly intervals. Compared with placebo, the 
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relative risks of clinical vertebral and hip fractures were 0.32 and 0.60, respectively. Clinical 
vertebral fractures occurred in 0.8% of women taking denosumab and 2.6% of control subjects. 
Hip fractures occurred in 1.2% of women on placebo and 0.7% on denosumab. The expected use 
is in women who cannot tolerate oral bisphosphonates. Other options in that situation include 
strontium ranelate and zoledronate, which, compared with placebo, also reduced the risk of 
clinical vertebral fractures [relative risks (RRs) 0.65 and 0.23, respectively]. Zoledronate also 
significantly reduced the risk of hip fractures (RR 0.59). The ERG concluded that zoledronate 
was the main comparator. The relative cost-effectiveness of denosumab and zoledronate depends 
mainly on assumptions about costs of administration.
Introduction
The National Institute for Health and Clinical Excellence (NICE) is an independent organisation 
within the NHS. One of the responsibilities of NICE is to provide guidance to the NHS on the use 
of selected new and established health technologies, based on an appraisal of those technologies.
NICE’s single technology appraisal (STA) process is specifically designed for the appraisal of a 
single product, device or other technology, with a single indication, where most of the relevant 
evidence lies with one manufacturer or sponsor.1 Typically, it is used for new pharmaceutical 
products close to launch. The principal evidence for an STA is derived from a submission by the 
manufacturer/sponsor of the technology. In addition, a report reviewing the evidence submission 
is submitted by the evidence review group (ERG), an external organisation independent of the 
Institute. This paper presents a summary of the ERG report for the STA entitled ‘Denosumab for 
the prevention of osteoporotic fractures in postmenopausal women’.2
Description of the underlying health problem
Postmenopausal osteoporosis has been defined as ‘… a progressive, systemic skeletal disorder 
characterised by low bone mass and micro-architectural deterioration of bone tissue, with a 
consequent increase in bone fragility and susceptibility to fracture’.3
It is estimated that there are 180,000 osteoporosis-related symptomatic fractures each year in 
England and Wales.3 Of these, 70,000 are hip fractures that require hospital admission and 
surgical treatment, and are associated with significant morbidity and mortality.3 In women over 
the age of 50 years, the lifetime risk of a hip fracture is one in five.3 A recent meta-analysis of all 
anti-osteoporosis drugs found that treatment reduces mortality.4
Scope of the ERG report
Bone is in a state of continuous breakdown and renewal. Breakdown is carried out by cells 
called osteoclasts and renewal by osteoblasts. The cytokine RANK-ligand plays a pivotal role in 
mediating osteoclast activity. Denosumab is a human monoclonal antibody that inhibits RANK-
ligand, thereby reducing osteoclast activity and hence bone breakdown.
Marketing authorization for denosumab has been granted by the Committee for Medicinal 
Products for Human Use (CHMP) of the European Medicines Agency (EMA).5
The manufacturer’s submission (MS) argued that denosumab was clinically effective and 
cost-effective in the prevention of osteoporotic fractures among postmenopausal women. The 
submission assumed that because of the low cost of oral bisphosphonates (OBPs), denosumab 
would be used in women who were unable to tolerate those drugs.
[3]
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In a large trial against placebo (the FREEDOM trial6), denosumab was shown to reduce fracture 
risk. The MS included evidence from studies comparing denosumab against several comparator 
treatments with changes in bone mineral density (BMD) as the primary end point. However, 
given that fracture rates have been reported in trials of denosumab and comparator treatments, 
that evidence was preferred, and information relating to BMD was not considered by the ERG.
Methods
The ERG report comprised a critical review of the evidence for the clinical effectiveness and cost 
effectiveness of denosumab presented in the MS to NICE.
Reviews of the clinical effectiveness of treatment for osteoporosis had been conducted7 to 
support the development of a NICE osteoporosis guideline.8 The manufacturer updated these by 
searching for studies published since these reviews. The ERG also conducted searches to identify 
if any relevant studies had been missed.
The control group in the FREEDOM trial6 was given placebo. The effectiveness of denosumab 
relative to other bone-loss therapies was therefore estimated from an indirect comparison using 
trials of other drugs against placebo, using the adjusted indirect comparison method described by 
Bucher and colleagues.9 Although not ideal, this is the only approach that could be adopted in the 
absence of head-to-head trials.
The ERG explored the challenges associated with the adjusted indirect comparison method, and 
considered whether differences in the baseline characteristics of studies included in the indirect 
comparison (which could modify the relevant treatment effect) had been taken into account by 
the manufacturer.
The manufacturer used an economic model that took account of costs from short-term drug 
costs to long-term nursing home costs. The ERG evaluated the model against the 10-point 
checklist developed by Drummond and colleagues10 and the NICE reference case.11 The ERG also 
sought opinion regarding assumptions made within the manufacturer’s model, following which 
the model was re-run after making adjustments based on the views and information received.
The manufacturer had also conducted a systematic review of economic studies assessing the costs 
and/or cost-effectiveness of denosumab. The ERG undertook further searches to identify if any 
relevant studies had been missed.
Results
Summary of submitted clinical evidence
The main evidence submitted was the FREEDOM trial of denosumab against placebo,6 and an 
indirect comparison of denosumab against other drugs.
The FREEDOM trial6 was a large, good-quality trial involving women with postmenopausal 
osteoporosis.12 Denosumab given by subcutaneous injection at 6-monthly intervals for 3 years 
was effective in reducing fractures. Hip fractures were reduced by 40%, from 1.2% of women in 
the placebo group to 0.7% in the denosumab group. Clinical vertebral fractures were reduced by 
69% from 2.6% in the placebo group to 0.8% in the denosumab group.
[4]
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Safety data are available from 30 studies with 14,000 patients, of whom 11,000 are 
postmenopausal women. Based on these studies, denosumab appears safe. However, a US Food 
and Drug Administration (FDA) summary of safety13 noted that people receiving denosumab 
appeared to have a slightly increased risk of serious infections of the skin, ear, urinary tract 
and abdomen. They also noted a non-significant increase in cancer incidence, and theoretical 
concerns about denosumab suppressing dynamic bone formation leading to delayed fracture 
healing and atypical fracture.13
Persistence with osteoporosis treatment is known to be poor for many existing drugs, such as 
the OBPs.14–16 It is likely that the 6-monthly administration in GP surgery or hospital clinic will 
encourage persistence with denosumab.
The MS stated that because of the availability of inexpensive generic OBPs ‘… denosumab 
is expected to be an appropriate option for diagnosed patients for whom oral BPs are 
unsuitable; reasons for unsuitability include inability to comply with the special instructions 
for administration, a contraindication or intolerance’ (p. 15). The drugs used in the indirect 
comparison were therefore strontium, raloxifene, teriparatide, zoledronate and intravenous (i.v.) 
ibandronate.
The indirect comparison included a comparison of the relative risks (RRs) of fracture for each 
drug versus placebo, and an adjusted estimation of the RR of fracture for denosumab versus the 
other drugs. This demonstrated that denosumab, strontium ranelate and zoledronate provided 
statistically significant decreases in the risk of clinical vertebral fractures (RRs of 0.32, 0.65 and 
0.23, respectively) compared with placebo, but raloxifene did not (RR of 0.45, not significant). 
Denosumab and zoledronate reduced the risk of hip fractures compared to placebo (RRs of 0.61 
and 0.59 respectively, both statistically significant) but strontium ranelate did not (RR 0.89, not 
significant). Data on the risk of wrist fractures relative to placebo were available for denosumab 
(RR 0.84) and strontium ranelate (RR 0.98), neither of which was statistically significant. No data 
on wrist fractures were available for zoledronate or raloxifene. The RRs obtained from the direct 
comparison of each drug with placebo were used to model cost-effectiveness.
Summary of submitted cost-effectiveness evidence
The manufacturer provided multiple comparisons of cost-effectiveness using a good-quality 
Markov model that took account of drug costs, administration and monitoring costs, costs 
associated with fractures, and long-term nursing home costs. Utility weights derived from a 
review of the literature were used to adjust time spent in fracture states, allowing quality-adjusted 
life-years (QALYs) to be estimated. The base-case analysis was conducted for 70-year old-women 
with a T-score of ≤ –2.5 and no prior fracture, and 70-year old-women with a T-score of ≤ –2.5 
with a prior fragility fracture. Subgroup analyses based on T-score and independent clinical risk 
factors were also undertaken. The analysis complied with the NICE reference case.
The submission argued that denosumab:
 ■ dominated strontium for both primary and secondary prevention, i.e. was both more 
effective and less costly
 ■ was cost-effective compared with raloxifene, with costs per QALY of £9289 in primary 
prevention and around £2000 in secondary prevention
 ■ could be cost-effective compared with no treatment in some subgroups of women without 
prior fracture, who might not be treated with a second drug if unable to tolerate OBPs, 
according to the current NICE guidance
 ■ could be cost-effective versus no treatment in women with fragility fractures (£12,381 per 
QALY).
[6]
[7]
[7]
UNCORRECTED PROOF
Date: 15:35 Tuesday 22 February 2011
File: hokkaido:Users:davidr:Documents:David R's WIP:HTA:Supplement 6:04 Typeset files:1st proof:v15suppl1-06_08-231-01 1P
© Queen’s Printer and Controller of HMSO 2011. All rights reserved.
55 Health Technology Assessment 2011; Vol. 15: Suppl. 1
 ■ dominated i.v. ibandronate
 ■ was cost-effective compared with zoledronate with the incremental cost-effectiveness ratio 
(ICER) for zoledronate versus denosumab reported to be £70,000 per QALY in women with 
no prior fracture and £29,000 in women with a prior fracture.
However, a key assumption was that denosumab would be given in general practice at the 
average cost of two standard GP visits a year. This would make it less costly than zoledronate, 
which is given by i.v. infusion, in hospital clinics, once a year. Given the similar effectiveness of 
denosumab and zoledronate, the cost-effectiveness comparison depended largely on the relative 
costs. The ERG were of the opinion that GPs would be likely to regard administration of a new 
biological agent as not part of General Medical Services, and might expect it to be part of an 
enhanced service. The ERG also expected that denosumab would be initiated in secondary care, 
and that patients might also be followed up in secondary care.
Commentary on the robustness of submitted evidence
Strengths
The key trials considered were of good quality, had large numbers of recruits and were of 
adequate duration. The economic model was of high quality. The submission and appendices 
provided very detailed accounts of underlying assumptions and sensitivity analyses.
Weaknesses
The manufacturer submitted a very large amount of material, far exceeding the NICE guidance 
on length of submission. However, the ERG considered the evidence of effects of drugs on bone 
mineral density to be not relevant, partly because of doubts about the value of BMD in assessing 
effects of most drugs in osteoporosis, but mainly because there were fracture data for all the 
drugs. Nor did the ERG consider the data on morphometric vertebral fractures to be useful, and 
it was noted that Amgen did not use such data in the modelling.
The Amgen submission argued that zoledronate and i.v. ibandronate should not be primary 
comparators because they were ‘not standard care’ and because they had not been appraised by 
NICE. Howeve, despite not having been appraised by NICE, both have been licensed for some 
time and are in routine use in the UK.
In the ERG’s opinion, the major weakness lay in the economic modelling of zoledronate versus 
denosumab. The ERG considered zoledronate to be a key comparator for denosumab, and the 
relative cost-effectiveness of these two drugs was sensitive to assumptions about relative costs of 
administering them.
If the cost of denosumab was increased, by assuming it would be delivered in secondary care, the 
ICER for denosumab compared with no treatment would rise to £36,185 per QALY in women 
with no prior fragility fracture, and to £15,720 per QALY in women with a prior fragility fracture. 
This change led to zoledronate dominating denosumab in women with and without a prior 
fragility fracture.
The ERG also re-ran the model, assuming equal efficacy of denosumab and zoledronate for 
the prevention of wrist fractures. This reduced the costs per QALY for zoledronate relative 
to denosumab by about £10,000 in primary prevention, and by about £5000 in secondary 
prevention.
The MS also examined the cost-effectiveness of denosumab in women who could not tolerate 
OBPs, but whose risk level meant that other drugs were not currently cost-effective, according to 
NICE Technology Appraisals (TAs) 160 and 161.3,17 The ERG considered this data and surmised 
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that denosumab might be considered cost-effective in some of these women if the manufacturer’s 
costing assumptions were to be accepted (assuming a cost-effectiveness threshold of £30,000 per 
QALY). This could provide a partial solution to the unsatisfactory situation in which clinicians 
could not offer an alternative treatment to women unable to tolerate OBPs until their clinical 
condition deteriorated.
Following advice from clinical experts, the NICE Appraisal Committee ‘ concluded that it is likely 
that treatment will be started in secondary care and subsequently delivered in primary care, but 
with follow up of women with severe osteoporosis in secondary care in accordance with current 
UK clinical practice’.
Conclusions
The clinical effectiveness of denosumab is not in doubt, and it appears safe. The key issue in the 
cost-effectiveness analysis is its cost relative to zoledronate. For women with no prior fragility 
fractures, its potential cost-effectiveness relative to no treatment in some groups is also highly 
relevant, as current NICE guidance recommends no treatment for many women in this group if 
they cannot tolerate OBPs.
Areas of uncertainty
The indirect comparison was necessary because of the lack of direct head-to-head trials. It 
appeared to be well done, but the ERG wondered if differences in baseline characteristics of 
the women in the trials (such as duration of follow-up, age, body mass index, proportion with 
previous fractures) would affect some comparisons.
Because of absence of data on the effect of zoledronate on wrist fractures, the Amgen modelling 
assumed that it would not reduce the incidence of those, whereas it was assumed that denosumab 
would, based on data from the FREEDOM trial.6 However, given the equivalence, or a non-
significant slight superiority, of zoledronate to denosumab, the ERG considered it unlikely that 
zoledronate would have no effect on wrist fractures.
In the modelling, the reduction in breast cancer incidence from raloxifene treatment was not 
included. This was raised with the manufacturer, who stated that this was in line with the 
precedent set in NICE TAs 160 and 161.
In the indirect comparison, data from a trial of oral ibandronate were used, and assumed to apply 
to i.v. ibandronate. However, the DIVA trial18 of oral versus i.v. ibandronate showed that the i.v. 
form, given at 3-monthly intervals, was more effective, with fracture incidence of 4.8% in the 
i.v. groups versus 6.2% in the oral group. This difference was at 2 years’ follow-up and was not 
statistically significant, but it could be used in a sensitivity analysis.
Two recent studies using data from British general practice have examined the risk of 
oesophageal cancer. The first, by Cardwell and colleagues,19 was a case–control study that started 
with OBP use, and compared oesophageal cancer rates in users versus age- and sex-matched 
control subjects who did not take OBPs. They found no increase in cancer risk [RR 1.07, 95% 
confidence interval (CI) 0.77 to 1.49]. The second, by Green and colleagues started with cancer 
cases, and compared OBP use in cancer cases and non-cancer controls. Green and colleagues,20 
concluded that the risk was increased in patients taking OBPs (RR 1.30, 95% CI 1.02 to 1.66). The 
difference may be explained by longer duration of OBPs use in the Green study,20 and a subgroup 
in the Cardwell study19 with longer use also has an increase (RR 1.23, 95% CI –0.66 to 0.2.30).
[3]
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Summary of NICE guidance (from FAD, as issued 8 September 2010)
1.1 Denosumab is recommended as a treatment option for the primary prevention of 
osteoporotic fragility fractures only in postmenopausal women at increased risk of fractures:
 ■ who are unable to comply with the special instructions for the administration of OBPs, are 
intolerant of OBPs or for whom treatment with OBPs is contraindicated and
 ■ who also have a combination of T-score, age and number of independent clinical risk factors 
for fracture (see section 1.3) as indicated in the following table.
1.2 Denosumab is recommended as a treatment option for the secondary prevention of 
osteoporotic fragility fractures only in postmenopausal women at increased risk of fractures who 
are unable to comply with the special instructions for the administering alendronate and either 
risedronate or etidronate, or have an intolerance of, or a contraindication to, those treatments.
1.3 For the purposes of this guidance, independent clinical risk factors for fracture are parental 
history of hip fracture, alcohol intake of four or more units per day, and rheumatoid arthritis.
1.4 People currently receiving denosumab for the primary or secondary prevention of 
osteoporotic fragility fractures who do not meet the criteria specified in recommendations 1.1 
or 1.2 should have the option to continue treatment until they and their clinician consider it 
appropriate to stop.
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